Developing non-opioid medicines for neuropathic pain
Nerve damage can disrupt the body's pain-control pathways, allowing excessive pain signals to persist. Neuropathic pain can become chronic, while existing treatments mainly address symptoms and have side effects and limited long-term efficacy.
Apateya is developing non-opioid AP Series medicines for neuropathic pain. Its compounds aim to restore the nervous system's own pain-inhibiting pathways, reducing excessive signals from the spinal cord to improve pain control.
What stands out about Apateya
Reports lead-candidate proof of concept and efficacy in multiple animal models in a 2025 SPARK investor booklet.
Spun out from Bordeaux’s Institut des Maladies Neurodégénératives to develop non-opioid treatments for neuropathic pain.
Co-founder Franck Aby holds a neuroscience PhD focused on pain sensitisation, directly relevant to neuropathic-pain drug development.
Joined Bpifrance's inaugural Deeptech Seed accelerator cohort in 2026 to prepare for fundraising.
The official development timeline records Innovaday and iPhD awards in 2023, before the company's 2024 incorporation.
Selected for Bordeaux Care Lab’s second health-incubator cohort, announced by Unitec in December 2024.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.